CTOs on the Move

Canary Medical

www.canarymedical.com

 
Canary Medical was conceived and created by a team of surgeons, medical device developers, and IoT experts with the vision that (1) healthcare transformation requires better and cheaper healthcare data, (2) better monitoring and better data will produce better outcomes at lower costs, and (3) the patient`s own their healthcare data and should be compensated for its use.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Canary Medical raised $10M on 05/17/2018

Similar Companies

AmpliMed Corporation

AmpliMed Corporation is a Tucson, AZ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

SkinMedica

SkinMedica, Inc. is a specialty pharmaceutical company focused on developing, acquiring and commercializing products that treat dermatologic conditions and diseases, and improve the appearance of skin. Through the Company's own sales force, it markets

StemoniX

StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.

Anika Therapeutics

Anika is a biomedical joint preservation company that leverages proprietary regenerative and restoration therapies to help people feel better faster and remain active. For nearly 30 years and 35 million procedures worldwide, Anika has been passionately advancing quality patient care by enabling people to continue doing what they love. Anika. Your life. In Motion.

Switch Therapeutics

Switch Therapeutics is an emerging preclinical stage biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet needs. Switch`s novel gene knockdown approach is based on technology developed by renowned researchers in the field of RNA from Caltech, Harvard and City of Hope. Based on the scientific discovery of Switch`s co-founders, the company has developed a novel proprietary platform known as CASi (Conditionally Activated siRNAs) that combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. To date, Switch has raised $52M in funding through Series A, and the company`s South San Francisco based team has continued to grow as its research has advanced.